Study of sonrotoclax, zanubrutinib and rituximab for untreated follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have follicular lymphoma (grade 1, 2, or 3a) that has not been treated before
- Your lymphoma must be at an advanced stage (III or IV), or stage II with a large tumor
- You must have at least one measurable or assessable area of disease
- You need to have symptoms or other signs that the lymphoma needs treatment (GELF criteria)
- You must be generally able to do daily activities (ECOG performance status of 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zuberitamab and bendamustine, for people with a type of lymphoma called follicular lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective, and then if keeping on one of the drugs alone helps keep the cancer from coming back.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.